Enhanced Protective Immunity Derived from Dendritic Cells with Phagocytosis of CD40 Ligand Transgene-engineered Apoptotic Tumor Cells via Increased Dendritic Cell Maturation

Abstract

Aims and Background

Dendritic cells (DCs) play a pivotal role in regulating CD8⁺ cytotoxic T-lymphocyte (CTL) responses. Currently, DC vaccines have been used in experimental animal models and clinical trials for evaluation of antitumor immunity. However, their efficacy is limited, warranting the improvement of DC-based cancer vaccines. CD40 ligand (CD40L) stimulates DC activation and maturation via CD40-CD40L interaction. We demonstrated that DCs that had phagocytized apoptotic tumor cells induced antitumor immunity.

Methods

We generated CD40L-expressing (EG7-CD40L) and the control (EG7-Null) EG7 tumor cells by transfection of EG7 tumor cells with CD40L-expressing adenoviral vector AdVCD40L and the control vector AdV_pLpA, respectively. We also generated DC vaccines (DC-EG7/CD40L and the control DC-EG7/Null) using DCs with phagocytosis of irradiated EG7-CD40L and EG7-Null tumor cells, and assessed their phenotype and immunogenicity by flow cytometry and animal studies in C57BL/6 mice.

Results

We demonstrate that an irradiation of 9000-rad induced Annexin V-expressing cell apoptosis in most (~75%) tumor cells, and provide evidence for phagocytosis of apoptotic tumor cells by flow cytometry and confocal microscopy. The DC-EG7/CD40L cells showed higher expression of DC maturation markers (Ia^b, CD40, CD80, and CD86) and peptide/major histocompatibility complex I than the control DC-EG7/Null cells. In addition, DC-EG7/CD40L vaccine stimulates more efficient (0.97%) tumor-specific CTL responses than DC-EG7/Null cells (0.31%). Furthermore, 80% (4/5) of mice immunized with DC-EG7/CD40L vaccine become tumor-free after EG7 tumor cell challenge, whereas DC-EG7/Null vaccine only delays immunized mouse death.

Conclusions

Dendritic cells that have phagocytized CD40L-expressing apoptotic tumor cells appear to offer new strategies in DC cancer vaccines.

Get full access to this article

View all access options for this article.

References

Tang

Type 1 CD8⁺ T cells are superior to type 2 CD8⁺ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation. Cell Mol Immunol 2007;4 (4):277–285

Klebanoff

Acquavella

Restifo

Therapeutic cancer vaccines: are we there yet?

Immunol Rev 2011;239 (1):27–44

Palucka

Ueno

Banchereau

Recent developments in cancer vaccines. J Immunol 2011;186 (3):1325–1331

Galluzzi

Senovilla

Vacchelli

Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012;1 (7):1111–1134

Vacchelli

Vitale

Eggermont

Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013;2 (10):e25771

Palucka

Banchereau

Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12 (4):265–277

Melief

Cancer immunotherapy by dendritic cells. Immunity 2008;29 (3):372–383

Figdor

de Vries

IJM

Lesterhuis

Melief

CJM

Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10 (5):475–480

Janikashvili

Larmonier

Katsanis

Personalized dendritic cell-based tumor immunotherapy. Immunotherapy 2010;2 (1):57–68

10.

Grewal

Flavell

CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16 (1):111–135

11.

Smith

Farrah

Goodwin

The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994;76 (6):959–962

12.

Banchereau

Steinman

Dendritic cells and the control of immunity. Nature 1998;392 (6673):245–252

13.

Schoenberger

Toes

REM

van der Voort

EIH

Offringa

Melief

CJM

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393 (6684):480–483

14.

Cohen

Apoptosis. Immunol Today 1993;14 (3):126–130

15.

Bellone

Iezzi

Rovere

Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 1997;159 (11):5391–5399

16.

Koh

Levine

Apoptosis and autoimmunity. Curr Opin Nephrol Hypertens 1997;6 (3):259–266

17.

Boisteau

Gautier

Cordel

Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line. Apoptosis 1997;2 (4):403–412

18.

Inaba

Turley

Yamaide

Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998;188 (11):2163–2173

19.

Rovere

Vallinoto

Bondanza

Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998;161 (9):4467–4471

20.

Albert

Sauter

Bhardwaj

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392 (6671):86–89

21.

Henry

Bretaudeau

Barbieux

Meflah

Gregoire

Induction of antigen presentation by macrophages after phagocytosis of tumour apoptotic cells. Res Immunol 1998;149 7-8:673–679

22.

Henry

Boisteau

Bretaudeau

Lieubeau

Meflah

Grégoire

Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999;59 (14):3329–3332

23.

Hoffmann

Meidenbauer

Dworacki

Kanaya

Whiteside

Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000;60 (13):3542–3549

24.

Jenne

Arrighi

J-F

Jonuleit

Saurat

J-H

Hauser

Dendritic cells containing apoptotic melanoma cells prime human CD8⁺ T cells for efficient tumor cell lysis. Cancer Res 2000;60 (16):4446–4452

25.

Liu

Qureshi

Xiang

Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells. Cancer Biother Radiopharm 2002;17 (1):11–18

26.

Chen

Moyana

Saxena

Warrington

Jia

Xiang

Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001;93 (4):539–548

27.

Liu

Zhang

Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(⁺) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther 2002;9 (2):202–208

28.

Xie

Bai

Yuan

Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-β1 inducing CD8⁺ T-cell anergy and CD4⁺ Tr1 cell responses. Cancer Res 2009;69 (19):7756–7766

29.

Liu

Xiang

Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses. Cancer Res 2005;65 (11):4955–4962

30.

Huang

Yuan

Guo

Xiang

Combined CD4⁺ Th1 effect and lymphotactin transgene expression enhance CD8⁺ Tc1 tumor localization and therapy. Gene Ther 2005;12 (12):999–1010

31.

Prabir

Giridhar

Zoya

Bhadrasain

Dendritic cells pulsed with irradiated prostate tumor cells express CC receptor-7 and its ligands and initiate a tumor specific immune response. J Cancer Molecules 2007;3:55–60

32.

O'Rourke

Johnson

Lanagan

Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother2003;52 (6):387–395

33.

Larmonier

Mérino

Nicolas

Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis 2006;11 (9):1513–1524

34.

Jarnjak-Jankovic

Pettersen

Saebøe-Larssen

Wesenberg

Olafsen

Gaudernack

Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther 2005;12 (8):699–707

35.

von Euw

Barrio

Furman

Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(⁺) T lymphocytes. J Transl Med 2007;5 (1):19

36.

Benencia

Courrèges

Coukos

Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med 2008;6 (1):21–21

37.

Tomita

Yamaguchi

Sugimoto

Takamori

Nagamune

Poly(ethylene glycol)-lipid-conjugated antibodies enhance dendritic cell phagocytosis of apoptotic cancer cells. Pharmaceuticals 2012;5 (5):405–416

38.

Xie

Wang

Freywald

Qureshi

Chen

Xiang

A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling. Cell Mol Immunol 2013;10 (1):72–77